Trials / No Longer Available
No Longer AvailableNCT06631677
Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)
An Open Label, Expanded Access Program of Dupilumab in Adults With Severe IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
This is an expanded access program of dupilumab that was never initiated and, therefore, not available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | Administered per protocol |
Timeline
- First posted
- 2024-10-08
- Last updated
- 2025-01-29
Source: ClinicalTrials.gov record NCT06631677. Inclusion in this directory is not an endorsement.